ArticleClinical transplantation2026
Dual Kidney Transplantation Offers Prolonged Graft Survival.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Outcomes of Dual Kidney Transplantation from Donors with High Pre-Implantation Biopsy Scores.American journal of nephrology · 2026Article
- Dual Kidney Transplantation Offers Prolonged Graft Survival.Clinical transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDual kidney transplantation (DKT), an uncommonly performed procedure, provides a unique opportunity to transplant nonstandard kidneys that might otherwise not be utilized. We compared perioperative and five-year posttransplant outcomes between DKT, and single kidney transplants (SKT) performed at our institution.
methodsWe analyzed all adult deceased donor kidney-alone transplant recipients at our center between 2001 and 2020. Recipients of pediatric en bloc kidney transplants were excluded. Perioperative outcomes of interest included delayed graft function (DGF), posttransplant length of stay (LOS), rehospitalization, and reoperation. Five-year outcomes included biopsy-proven acute rejection (AR), death-censored graft failure (DCGF), uncensored graft failure (UCGF), and death with functioning graft (DWFG).
resultsA total of 100 DKT and 3125 SKT recipients were included. DKT recipients were older (p < 0.001), more often male (68%), and more often underwent early steroid withdrawal (p = 0.04). In comparison to SKT, after adjustment for multiple variables, DKT was not independently associated with DGF (aOR: 1.25; 95% CI 0.76-2.08); prolonged LOS (linear coefficient 0.42; -0.9-1.7); reoperation (aOR: 0.73; 95% CI: 0.21-2.51) or rehospitalization (aOR 0.98; 95% CI: 0.55-1.74). However, within five years, DKT had a lower adjusted incidence rate ratio (aIRR) for AR (aIRR: 0.28; CI 0.12-0.64); DCGF (aIRR: 0.30; 95% CI 0.13-0.68), and UCGF (aIRR: 0.53; 95% CI: 0.33-0.86), without statistically significant differences in DWFG (aIRR: 0.83; 95% CI: 0.46-1.53).
conclusionIn selected recipients, DKT offered superior medium-term outcomes compared to SKT without compromising perioperative outcomes. DKT can mitigate concerns associated with medically complex donor kidneys, increase organ utilization, and increase access to transplantation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.